
Sovaldi's Cost-Effectiveness is Being Overplayed
Bottom line: Sovaldi will not save the system money. It will cost money-a lot of money-to reduce premature mortality due to chronic hepatitis C infection.
"Research on the cost-effectiveness of Sovaldi is still in the early stages, but it appears that use of the drug has the potential to actually save money over the long run.” —New York Times UpShot column, Aug. 2
Nothing could be further from the truth.
A detailed analysis of cost-effectiveness studies, which appeared six years ago in the
Read the full story here:
Source: Modern Healthcare
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.